US Stock Insider Trading | Streamex disclosed one insider trading transaction on February 4

K-LinePoet · 2026-02-19T03:04:33+00:00

On February 4, 2026, Streamex disclosed that internal shareholder GIUSTRA FRANK purchased 100,000 shares on that day, with a total transaction amount of $317,000. Additionally, other shareholders have recently made multiple buy transactions. Streamex is a medical device company specializing in digital signal processing technology in the cardiovascular field.

K-LinePoet

2026-02-19 03:04:33

Abstract generation in progress

On February 4, 2026, Streamex (STEX) disclosed an insider transaction. Shareholder GIUSTRA FRANK, holding more than 10% of shares, purchased 100,000 shares on February 4, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 4, 2026	Shareholder with over 10%	GIUSTRA FRANK	February 4, 2026	Buy	100,000	3.17	317,000
February 3, 2026	Shareholder with over 10%	Lekstrom Morgan Lee	February 3, 2026	Buy	23,500	3.06	72,100
January 29, 2026	Shareholder with over 10%	Lekstrom Morgan Lee	January 29, 2026	Buy	2,500	3.70	9,250
January 23, 2026	Shareholder with over 10%	GIUSTRA FRANK	January 27, 2026	Buy	1,000,000	3.00	3,000,000
January 26, 2026	Shareholder with over 10%	Lekstrom Morgan Lee	January 26, 2026	Buy	23,000	3.30	75,900
January 27, 2026	Shareholder with over 10%	Lekstrom Morgan Lee	January 27, 2026	Buy	5,500	3.12	17,200
January 23, 2026	Executive	Williams Mitchell Young	January 23, 2026	Buy	51,500	3.03	155,900
January 23, 2026	Director	Lekstrom Morgan Lee	January 23, 2026	Buy	41,000	3.13	128,500
November 21, 2025	Director	Lekstrom Morgan Lee	November 21, 2025	Buy	7,000	3.58	25,100
August 14, 2025	Shareholder with over 10%	GIUSTRA FRANK	September 15, 2025	Buy	128,200	3.90	500,000

[Company Information]

Streamex Corp. was incorporated on February 24, 2009, under Nevada law and re-registered in Delaware in 2011. The company is a medical device firm with an advanced digital signal processing platform that provides insights for the treatment of cardiovascular arrhythmias. Initially, the company focused on providing intracardiac signal information to electrophysiologists during EP studies and catheter ablation of AF and VT. Its first product is the PURE EP system, an electronic mapping system that offers precise, continuous real-time assessment, capable of acquiring, processing, and displaying ECG and intracardiac signals needed during electrophysiological research and catheter ablation procedures.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes